The DEK oncogene was initially identified as a target of recurrent t(6;9) translocation, resulting in a fusion with the nuclear pore complex protein-encoding gene NUP214 in a subset of patients with acute myeloid leukemia (AML) [1, 2]. The gene discussed is DEK; the disease is acute myeloid leukemia.